{"schema_version":"secwatch.filing_event.v1","accession":"0000950123-21-010437","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.251478+00:00","generated_at":"2026-06-29T12:49:50.405291+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Schrödinger Q2 revenue up 29% to $29.8M; net loss widens to $34.6M on investment spend","bullets":["Total revenue $29.8M (+29% YoY); software revenue $24.1M (+15% YoY); drug discovery revenue $5.7M.","Net loss $34.6M vs $3.4M loss Q2 2020, driven by fair-value adjustments and R&D investments.","Announced global oncology collaboration with Zai Lab; eligible for up to ~$338M milestones and U.S. profit share.","Pipeline advancing: plans to submit up to three INDs to FDA in 2022, first IND expected H1 2022.","Full-year 2021 guidance maintained: total revenue $124M-$142M, software revenue $102M-$110M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950123-21-010437","json":"https://secwatch.observer/filing/0000950123-21-010437.json","markdown":"https://secwatch.observer/filing/0000950123-21-010437.md","text":"https://secwatch.observer/filing/0000950123-21-010437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000095012321010437/0000950123-21-010437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000095012321010437/FINAL-sdgr-8k_20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:49:50.405291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}